Observational study suggests that an early one-week treatment at the first sign of viral reactivation may achieve clinical benefits and avoid antiviral toxicity.
Both HHV-6 and specific microRNAs may correlate with neurological symptoms in COVID-19.
Assay for monkeypox virus, HSV1-2, HHV-6, VZV and enteroviruses.
HHV-6 was the most common herpesvirus found when tested in nasal swabs, but EBV was the most common in plasma.
Pityriasis rosea was reported more frequently after vaccination than during or after acute infection.
Patients with viral loads suggestive of iciHHV-6 had the greatest risk of developing demyelinating disease.
1.1% of 72,423 HCT patients developed encephalitis with an all-cause mortality rate of 60%.
Clinical assessment revealed that 91% of iciHHV-6 cases and 33% of non-iciHHV-6 cases were incidental.
All cases found to be iciHHV-6 were assumed to be false positives.
HHV-6A was the most common virus identified, but was not linked to worse outcomes compared to other viral infections.
The HHV-6 field has lost a pioneer.
Ribavarin, ritonavir, abacavir and lamivudine were the primary triggers.
CSF foscarnet concentrati.ons were very near IC50 and were followed by sharp reductions in viral load.
Transcription of HHV-6 genes was rare, but occurred most often in cells with the highest levels of EBV transcription.
Systematic review and meta-analysis found strong evidence for EBV in the seriously ill; only 6 of 36 studies included HHV-6 testing.